Seer, Inc. 8-K

What Happened Seer, Inc. announced on March 30, 2026, that the U.S. Patent & Trademark Office’s Patent Trial and Appeal Board (PTAB) issued a Final Written Decision on March 23, 2026, in inter partes review IPR2024-01473 of U.S. Patent No. 11,435,360 B2. The IPR was filed by PreOmics GmbH and Biognosys AG. The PTAB found that the petitioners failed to show claims 2, 3, 7, 23 and 24 were unpatentable, leaving a total of 23 claims — the five upheld plus 18 unchallenged — valid and enforceable. The filing also identifies certain challenged claims as unpatentable; it includes an apparent inconsistency regarding claim 24 (see filing and attached press release for the company’s full statements). Either party must file a notice of appeal by May 25, 2026.

Key Details

• Decision date: PTAB Final Written Decision issued March 23, 2026; Seer announced March 30, 2026.
• IPR case: IPR2024-01473, petitioners PreOmics GmbH and Biognosys AG.
• Patent: U.S. Patent No. 11,435,360 B2 — 23 claims remain valid and enforceable (five expressly upheld; 18 were unchallenged).
• Appeal deadline: Notice of appeal must be filed by May 25, 2026.
• Exhibit: Seer attached a press release as Exhibit 99.1 to the 8-K.

Why It Matters For investors, the PTAB decision means Seer retains significant enforceable patent coverage for its particle proteomics technology, including claims tied to detection depth, dynamic range, and particle characteristics — protections that can support competitive position, licensing and commercialization. The outcome reduces near‑term legal risk from this specific IPR challenge, although the listed appeal deadline means the matter could still proceed if either party appeals.